FEI SHEN

Fei Shen is a distinguished Managing Director at the Boehringer Ingelheim Venture Fund (BIVF), a strategic corporate venture capital fund dedicated to investing in pioneering life science companies. In her role, Fei is instrumental in shaping the future of healthcare by identifying and supporting innovative startups that have the potential to deliver significant breakthroughs in medicine and technology.

At BIVF, Fei Shen's responsibilities encompass the full spectrum of venture capital activities, from deal sourcing and rigorous due diligence to leading investment rounds and providing strategic guidance to portfolio companies. Her expertise lies in evaluating complex scientific and technological innovations, assessing market potential, and fostering partnerships that accelerate growth and development. The fund's investment thesis is closely aligned with Boehringer Ingelheim's core areas of interest, including novel therapeutics for challenging diseases, advanced digital health solutions, and cutting-edge platform technologies that can transform drug discovery and development. Fei actively seeks out opportunities in areas such as immunology, oncology, respiratory diseases, cardiometabolic disorders, and central nervous system disorders, as well as emerging fields like gene therapy and microbiome research.

While specific details of her career background are not publicly available, a Managing Director at a leading corporate venture fund like BIVF typically possesses a strong foundation in science, medicine, or business, often coupled with extensive experience in the pharmaceutical or biotechnology industry. This background equips Fei with a deep understanding of the scientific landscape, regulatory pathways, and commercialization challenges inherent in the life sciences sector. Her strategic insights are invaluable in guiding early stage companies through critical development milestones and preparing them for future success.

Although individual notable investments are often confidential, Fei Shen's work contributes to a robust portfolio of companies that are at the forefront of medical innovation. Her commitment to fostering scientific excellence and strategic collaboration helps these ventures translate groundbreaking research into tangible solutions for patients worldwide. Through her leadership at BIVF, Fei Shen plays a crucial role in advancing Boehringer Ingelheim's mission to improve human and animal health by investing in the next generation of life science leaders.